Halodine, LLC marketed unapproved nasal and oral antiseptic drugs with COVID-19 prevention and treatment claims, FDA says.
What happened
FDA reviewed Halodine's websites and social media on June 23, 2021, plus product packaging, and found the nasal and oral antiseptic products promoted to prevent, treat, or cure COVID-19. The claims included killing SARS-CoV-2 in less than 15 seconds and providing up to 4 hours of protection. FDA says the products are unapproved new drugs and misbranded.
What FDA found
The nasal and oral antiseptic products are unapproved new drugs because FDA says they lack an approved application and are not generally recognized as safe and effective for their labeled uses.
section 505(a) of the FD&C Act, 21 U.S.C. 355(a)The product labeling is false or misleading because it says 'Halodine complies with FDA OTC regulations' even though FDA says the products are not legally marketed under section 505G.
section 502(a) of the FD&C Act, 21 U.S.C. 352(a)The products are misbranded nonprescription drugs because they are subject to section 505G but do not meet its marketing requirements and have no approved application.
section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)The nasal products are labeled for use inside the nostrils, which FDA says is not permitted for OTC consumer or health care antiseptics under the applicable monograph.
1994 TFM, 59 FR 31402, as amendedThe labeling claims go beyond allowed antiseptic uses, including claims of up to 4 hours of efficacy and shortening infection, and FDA says these claims are not permitted under the OTC monograph.
section 505G(a)(3) of the FD&C Act, 21 U.S.C. 355h(a)(3); Oral Antiseptics Proposed Rule, 59 FR 6084FDA says introducing these products into interstate commerce is prohibited.
sections 301(a) and (d) of the FD&C Act, 21 U.S.C. 331(a) and (d)
What FDA wants
FDA tells Halodine to immediately stop selling the products for COVID-19 and other unapproved uses and to email a description of corrective steps within 48 hours. If it cannot complete action in 48 hours, it must explain the delay and give a timeline.
Who should pay attention
- companies selling antiseptics or sanitizers with COVID-19 claims
- retailers and online marketplaces offering similar OTC antiseptic products
- quality teams reviewing website, social media, and label claims for OTC drugs
This is a summary. Read the original letter on fda.gov.